Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Recurrence 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Breast Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Proteostasis Deficiencies × ixazomib × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡